T细胞共刺激阻断通过抑制肾脏Th17细胞改善实验性膜性肾病
在Fx1A免疫诱导的Heymann肾炎大鼠模型中,CTLA4-Ig单用或联合短程硼替佐米均显著降低血清肌酐和蛋白尿、减轻肾脏组织学损伤,并减少肾内Th17细胞因子表达,提示CTLA4-Ig可能通过抑制肾脏Th17细胞改善实验性膜性肾病。
要点
- CTLA4-Ig单用或联合短程硼替佐米均显著降低HN大鼠血清肌酐和蛋白尿。
- CTLA4-Ig治疗减少肾小球IgG沉积,但各组血清抗Fx1A水平无显著差异。
- CTLA4-Ig可能通过抑制肾脏Th17细胞发挥疗效,可作为膜性肾病辅助治疗。
核心结论
- CTLA4-Ig可改善实验性膜性肾病的诱导,可能通过抑制肾脏Th17细胞发挥作用。
- CTLA4-Ig可能成为膜性肾病的有效辅助治疗。
研究设计与样本
- Lewis大鼠经Fx1A和完全弗氏佐剂免疫诱导Heymann肾炎模型。
- 大鼠接受CTLA4-Ig单用或CTLA4-Ig联合短程硼替佐米治疗,第12周评估。
- 评估指标包括血清肌酐、蛋白尿、肾脏组织学、血清抗Fx1A水平、肾和脾mRNA表达及脾细胞流式细胞术。
主要发现
- CTLA4-Ig治疗组和CTLA4-Ig联合硼替佐米治疗组血清肌酐和蛋白尿显著且相似地降低,肾脏组织学损伤较未治疗HN大鼠减轻。
- CTLA4-Ig治疗组和联合治疗组肾小球IgG沉积较未治疗HN大鼠减少,但血清抗Fx1A水平无显著差异。
- CTLA4-Ig治疗组和联合治疗组肾脏中Th17细胞因子(IL-6、IL-17、IL-21)及调节性T细胞标志物(Foxp3、TGF-β)表达显著降低,脾脏中无此变化。
- CTLA4-Ig联合硼替佐米治疗组和CTLA4-Ig治疗组CD4+及细胞内STAT3+细胞免疫组化染色较未治疗HN大鼠减少。
- 流式细胞术显示CTLA4-Ig减少B细胞和浆细胞,但不减少T细胞亚群。
临床怎么用
- CTLA4-Ig可能作为膜性肾病的辅助治疗选择,尤其针对T细胞依赖的B细胞活化途径。
- 联合短程硼替佐米未显示优于CTLA4-Ig单用的疗效,但耐受性和安全性需进一步评估。
局限性
- 研究为动物实验(Heymann肾炎大鼠模型),结果不能直接外推至人类膜性肾病。
- 未报告样本量、具体P值及效应量等统计细节。
- CTLA4-Ig减少B细胞和浆细胞但未显著降低血清抗Fx1A水平,机制仍需进一步阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Recent advances in membranous nephropathy treatment have focused on B cell depletion, which is incompletely effective, potentially due to persistent autoantibody-producing plasma cells or alternative pathways of injury. T cell costimulatory blockade [cytotoxic-T-lymphocyte-associated antigen 4 (CTLA4)-Ig] to prevent T cell-dependent B cell activation and short-course proteasome inhibition (bortezomib) to deplete plasma cells may represent a complementary form of treatment. METHODS: Lewis rats were immunized with Fx1A and complete Freund's adjuvant to induce experimental membranous nephropathy (Heymann nephritis or HN) and treated with CTLA4-Ig alone or CTLA4-Ig plus a short-course of bortezomib. Serum creatinine, proteinuria, kidney histology, serum anti-Fx1A levels, kidney and spleen messenger RNA expression, and flow cytometry on splenocytes were evaluated at 12 weeks. RESULTS: CTLA4-Ig-treated and CTLA4-Ig plus bortezomib-treated rats had significant and similar reductions in serum creatinine and proteinuria, with less histological kidney injury compared with untreated HN rats. Glomerular IgG deposition was reduced in CTLA4-Ig-treated and CTLA4-Ig plus bortezomib-treated rats compared with untreated HN rats but there were no significant differences in serum anti-Fx1A levels. CTLA4-Ig-treated and CTLA4-Ig plus bortezomib-treated rats exhibited significantly reduced T helper (Th)-17 cell cytokines (interleukin-6, -17, -21) and regulatory T cell (Foxp3, TGF-β) expression in the kidney but not the spleen. Immunohistochemical staining of CD4+ and intracellular STAT3+ cells was reduced in CTLA4-Ig plus bortezomib-treated and CTLA4-Ig-treated compared with untreated HN rats. On flow cytometry, CTLA4-Ig reduced B cells and plasma cells but not T cell subsets. CONCLUSIONS: CTLA4-Ig ameliorated induction of experimental membranous nephropathy, potentially through suppression of Th17 cells in the kidney, and may represent an effective adjunct treatment in membranous nephropathy.
引用
- Chung EYM, Wang YM, Shaw K, et al. T cell costimulatory blockade ameliorates induction of experimental membranous nephropathy potentially through T-helper 17 cell suppression in the kidney. Nephrol Dial Transplant. 2025. PMID: 39919766. doi:10.1093/ndt/gfaf030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。